Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus ...

UK experts have recommended that only a small group of high-risk men should be eligible for regular testing for prostate ...

Discover histotripsy, a non-invasive ultrasound cancer treatment that liquefies tumor cells, revolutionising patient care and ...

Company to explore the potential of integrating TULSA-PRO with PSMA PET molecular imaging technologies to enhance ablation planning and monitoringTORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound ...

HistoSonics, a company founded by biomedical engineer Zhen Xu in 2009, is developing a technique called histotripsy to target ...

Histotripsy uses focused sound waves to destroy cancer tumors without surgery, earning FDA approval and a $2.9B valuation for ...

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced that nine ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...

A multi-billion-dollar acquisition within the radiopharmaceutical space could be percolating as Lantheus Holding considers a ...

May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix ...

Explore why whole-body scans attract investors while doctors warn against them due to overdiagnosis and lack of evidence.

The non-invasive focused ultrasound system destroys liver tumours without surgery or radiation. Backed by Bezos Expeditions and valued at $2.25 billion, HistoSonics also submitted to the FDA for ...